(Q38116766)

29 August 2017

title

Complementing insulin therapy to achieve glycemic control (English)

1 reference

29 August 2017

1 reference

Anthony H Barnett

1

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 June 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

30

1 reference

29 August 2017

issue

6

1 reference

29 August 2017

page(s)

557-576

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-013-0039-y

29 August 2017

exact match

0 references

cites work

Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES).

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Prevalence of diabetic retinopathy in the United States, 2005-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Defining and characterizing the progression of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Short-term intensive insulin therapy in newly diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Treatment of type 2 diabetes with combined therapy: what are the pros and cons?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Early insulin use in type 2 diabetes: what are the cons?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Early insulin treatment in type 2 diabetes: what are the pros?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Three-year efficacy of complex insulin regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Severe hypoglycemia and risks of vascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Insulin-associated weight gain in diabetes--causes, effects and coping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

The barrier of hypoglycemia in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Hypoglycaemia in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Mechanism by which metformin reduces glucose production in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Combination of insulin and metformin in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, para

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Types and origins of diagnostic errors in primary care settings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Glucose control in diabetes: the impact of racial differences on monitoring and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

SGLT2 inhibition--a novel strategy for diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Relative expression of a dominant mutated ABCC8 allele determines the clinical manifestation of congenital hyperinsulinism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Induction of Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients by Transient Intensive Insulin Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0039-Y

10.1007/S12325-013-0039-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1034150496

0 references

Fatcat ID

release_v2tfiwrym5gwdgmf7bavrc6qxy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v2tfiwrym5gwdgmf7bavrc6qxy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference